GH3 International, Inc. (GHTI.PK) announced that its Licensed Clinic for GH3 therapy and its sister company generated in excess of $2.1 million revenues in 2005. Flo Ternes, President/CEO, said, �The G-H-3 Plus therapy is a natural fit for the clinic, and we look forward to finalizing our start up of the program which will be announced in the near future to expand our anti-aging treatment which has favorably improved adverse medical conditions.� Additional information can be found on our website at www.gh3international.com A number of statements contained in this press release are forward-looking statements, which are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development, and market acceptance conditions, successful integration of acquisitions and the ability to secure additional sources of financing. The actual results that GHTI may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.
GH3 (CE) (USOTC:GHTI)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse GH3 (CE)
GH3 (CE) (USOTC:GHTI)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse GH3 (CE)